Three experts discuss the increased mortality risk for patients with diabetic retinopathy, available screening tools, and ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

As a retina specialist, one of the most important aspects of eye care I focus on is the prevention and treatment of diabetic retinopathy. This condition is a leading cause of blindness in adults, yet ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...

In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...